330 related articles for article (PubMed ID: 31292267)
1. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).
Merten R; Ott O; Haderlein M; Bertz S; Hartmann A; Wullich B; Keck B; Kühn R; Rödel CM; Weiss C; Gall C; Uter W; Fietkau R
Oncologist; 2019 Dec; 24(12):e1341-e1350. PubMed ID: 31292267
[TBL] [Abstract][Full Text] [Related]
2. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.
Wittlinger M; Rödel CM; Weiss C; Krause SF; Kühn R; Fietkau R; Sauer R; Ott OJ
Radiother Oncol; 2009 Nov; 93(2):358-63. PubMed ID: 19837472
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
5. [Radiochemotherapy for invasive bladder cancer : An update].
Tselis N; Prott FJ; Ott O; Weiss C; Rödel C
Urologe A; 2018 Jun; 57(6):679-685. PubMed ID: 29651707
[TBL] [Abstract][Full Text] [Related]
6. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.
Rödel C; Grabenbauer GG; Kühn R; Papadopoulos T; Dunst J; Meyer M; Schrott KM; Sauer R
J Clin Oncol; 2002 Jul; 20(14):3061-71. PubMed ID: 12118019
[TBL] [Abstract][Full Text] [Related]
7. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.
Riesterer O; Ademaj A; Puric E; Eberle B; Beck M; Gomez S; Marder D; Oberacker E; Rogers S; Hälg RA; Kern T; Schwenne S; Stein J; Stutz E; Timm O; Zschaeck S; Weyland MS; Veltsista PD; Wyler S; Wust P; Scheidegger S; Bodis S; Ghadjar P
Int J Hyperthermia; 2022; 39(1):1078-1087. PubMed ID: 35993234
[TBL] [Abstract][Full Text] [Related]
8. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
9. [Bladder preservation by chemoradiotherapy in combination with radical TUR-Bt in muscle invasive bladder cancer].
Ishioka J; Kageyama Y; Ichiyanagi N; Saito Y; Nozu S; Nishida K; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2007 Sep; 98(6):752-6. PubMed ID: 17929456
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis].
Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240
[No Abstract] [Full Text] [Related]
12. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiation for organ preservation in the treatment of muscle invasive bladder cancer: Our Institutional Experience.
Gupta S; De S; Leekha N; Sahay SC; Chaudary P; Srinivasan S; Nandy M
Gulf J Oncolog; 2016 Sep; 1(22):55-60. PubMed ID: 28191808
[TBL] [Abstract][Full Text] [Related]
15. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
16. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
17. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Mitin T; George A; Zietman AL; Heney NM; Kaufman DS; Uzzo RG; Dreicer R; Wallace HJ; Souhami L; Dobelbower MC; Sandler HM; Shipley WU
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):67-74. PubMed ID: 26700703
[TBL] [Abstract][Full Text] [Related]
19. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
